Program
brivekimig
Also written as “SAR442970” and “Brivekimig”.
In Sanofi's pipeline, TNFaxOX40L Nanobody VHH
. Its studies are mostly in Hidradenitis Suppurativa · Glomerulosclerosis, Focal Segmental · Crohn Disease · Colitis, Ulcerative · Diabetes Mellitus, Type 1, led by Sanofi.
Furthest: phase 2, since Apr 28, 20236 company-led studies, 5 open or runningNext primary completion: Dec 17, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 65 open or running | phase 2since Apr 28, 2023 | Apr 28, 2023 | Dec 17, 2026phase 2 · NCT06958536 |
- Named in Sanofi’s own pipeline as
brivekimig
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 28, 2023First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT05849922 · 86 enrolled · United States, Australia, Belgium and more
- Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
- Jan 31, 2025Phase 2 study in Diabetes Mellitus, Type 1NCT06812988 · 84 enrolled · United States, Argentina, Australia and more
- Apr 25, 20252 phase 2 studiesNCT06958536, NCT06975722
- Sep 5, 2025Phase 2 study in Hidradenitis SuppurativaNCT07170917 · 208 planned · United States, Australia, Canada and more
Ahead
- Dec 17, 2026Primary completion: phase 2 study in Colitis, UlcerativeNCT06975722
- Dec 17, 2026Primary completion: phase 2 study in Crohn DiseaseNCT06958536
- Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
- Feb 9, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07170917
TargetBeta
“TNFaxOX40L Nanobody VHH”the company's pipeline, read by Claude · source
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07170917Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Recruiting | Feb 9, 2027 | 208 |
| NCT06975722Colitis, Ulcerative · United States, Australia, China and more | 2 | Active, not recruiting | Dec 17, 2026 | 105 |
| NCT06958536Crohn Disease · United States, Australia, Belgium and more | 2 | Recruiting | Dec 17, 2026 | 99 |
| NCT06812988Diabetes Mellitus, Type 1 · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 29, 2027 | 84 |
| NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more | 2 | Recruiting | Dec 23, 2026 | 84 |
| NCT05849922Hidradenitis Suppurativa · United States, Australia, Belgium and more | 2 | Completed | Aug 22, 2024 | 86 |
How it is read
Names in the registry
- “brivekimig”, 2 entries
- “SAR442970”, 2 entries
- “Brivekimig”, 2 entries
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 2 studies
- Glomerulosclerosis, Focal Segmental, 1 study
- Crohn Disease, 1 study
- Colitis, Ulcerative, 1 study
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.